Skip to main content
. 2022 Jan 19;8(3):eabj5908. doi: 10.1126/sciadv.abj5908

Fig. 8. Modeling infection of the p6G1634R HEV variant and testing antiviral drugs in liver-derived organoids.

Fig. 8.

(A) Replication (intracellular) and production (extracellular) of the HEV variant in fetal (FLO3) and adult (ALO2) ICOs. (B) Immunofluorescence staining of virus dsRNA in organoids electroporated with p6G1634R. (C) Immunofluorescence staining of HEV ORF2 protein in organoids electroporated with p6G1634R. (D) Quantification of viral RNA in HepG2 cells inoculated with extracellular HEV from organoid supernatant (n = 3). (E) Immunofluorescence staining of HEV ORF2 in Huh7 cells at 48 hours after inoculation. (F) The inhibitory effect of ribavirin in p6G1634R organoids or p6 organoids (FLO1, n = 4 to 6). (G) The inhibitory effect of brequinar in p6G1634R organoids (FLO1, n = 4 to 5). (H) The inhibitory effect of homoharringtonine in p6G1634R organoids (FLO1, n = 4 to 5). Data are presented as means ± SD, *P < 0.05 and **P < 0.01.